Rapport Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Danielle Brill from Truist Financial maintained a Buy rating on the stock and has a $56.00 price target.

Claim 55% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Danielle Brill has given his Buy rating due to a combination of factors tied primarily to the potential of RAP-219 in focal onset seizures and the corresponding valuation upside. He views the Phase 2 open-label results as highly encouraging, with seizure reduction and seizure-freedom rates that appear superior to leading competitors, while maintaining a favorable safety profile with limited psychiatric side effects so far.

Brill’s discounted cash flow work, which assumes conservative pricing versus some peers and only partial probability of success, still supports substantial peak revenue in FOS alone and a higher price target of $56 per share. He also highlights bipolar disorder as an additional upside opportunity that is not fully embedded in his base-case model, arguing that, if RAP-219’s efficacy and tolerability are confirmed in larger trials, RAPP could justify a valuation at least in line with or above current best-in-class epilepsy developers despite acknowledged trial and data-size risks.

In another report released on May 12, Stifel Nicolaus also maintained a Buy rating on the stock with a $56.00 price target.